Calcitonin Gene-Related Peptide
"Calcitonin Gene-Related Peptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A 37-amino acid peptide derived from the calcitonin gene. It occurs as a result of alternative processing of mRNA from the calcitonin gene. The neuropeptide is widely distributed in the brain, gut, perivascular nerves, and other tissue. The peptide produces multiple biological effects and has both circulatory and neurotransmitter modes of action. In particular, it is a potent endogenous vasodilator.
| Descriptor ID |
D015740
|
| MeSH Number(s) |
D12.644.400.097 D12.776.631.650.097
|
| Concept/Terms |
Calcitonin Gene-Related Peptide- Calcitonin Gene-Related Peptide
- Calcitonin Gene Related Peptide
- Gene-Related Peptide, Calcitonin
- Peptide, Calcitonin Gene-Related
|
Below are MeSH descriptors whose meaning is more general than "Calcitonin Gene-Related Peptide".
Below are MeSH descriptors whose meaning is more specific than "Calcitonin Gene-Related Peptide".
This graph shows the total number of publications written about "Calcitonin Gene-Related Peptide" by people in this website by year, and whether "Calcitonin Gene-Related Peptide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2004 | 1 | 0 | 1 |
| 2008 | 0 | 2 | 2 |
| 2010 | 0 | 2 | 2 |
| 2012 | 1 | 1 | 2 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 1 | 2 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 2 | 3 |
| 2017 | 3 | 0 | 3 |
| 2018 | 3 | 4 | 7 |
| 2019 | 1 | 1 | 2 |
| 2020 | 1 | 1 | 2 |
| 2021 | 0 | 2 | 2 |
| 2022 | 0 | 2 | 2 |
| 2023 | 0 | 2 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Calcitonin Gene-Related Peptide" by people in Profiles.
-
Porreca F, Dodick DW. Considering Patient Sex in Prescribing CGRP Receptor Antagonists for Short-Term Treatment of Migraine. JAMA Neurol. 2023 09 01; 80(9):885-886.
-
George N, Tepper SJ. Novel Migraine Treatments: A Review. J Oral Facial Pain Headache. 2023 Winter; 37(1):27-34.
-
Cohen F, Yuan H, Silberstein SD. Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale. BioDrugs. 2022 May; 36(3):341-358.
-
Medrea I, Christie S, Tepper SJ, Thavorn K, Hutton B. Effects of acute and preventive therapies for episodic and chronic cluster headache: A scoping review of the literature. Headache. 2022 Mar; 62(3):329-362.
-
Nahas SJ, Naegel S, Cohen JM, Ning X, Janka L, Campos VR, Krasenbaum LJ, Holle-Lee D, Kudrow D, Lampl C. Efficacy and safety of fremanezumab in clinical trial participants aged =60?years with episodic or chronic migraine: pooled results from 3 randomized, double-blind, placebo-controlled phase 3 studies. J Headache Pain. 2021 Nov 24; 22(1):141.
-
Yan BM, Gibson Depoy EM, Ahmad A, Nahas SJ. Biomarkers in Migraine. Neurol India. 2021 Mar-Apr; 69(Supplement):S17-S24.
-
Silberstein S, Diamond M, Hindiyeh NA, Biondi DM, Cady R, Hirman J, Allan B, Pederson S, Schaeffler B, Smith J. Eptinezumab for the prevention of chronic migraine: efficacy and safety through 24?weeks of treatment in the phase 3 PROMISE-2 (Prevention of migraine via intravenous ALD403 safety and efficacy-2) study. J Headache Pain. 2020 Oct 06; 21(1):120.
-
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 09; 19(9):727-737.
-
Tepper SJ. CGRP and headache: a brief review. Neurol Sci. 2019 May; 40(Suppl 1):99-105.
-
Dodick DW. CGRP ligand and receptor monoclonal antibodies for migraine prevention: Evidence review and clinical implications. Cephalalgia. 2019 03; 39(3):445-458.